🚀 Pharmidex at OBN Science Social – Join Us! 🔬
February 12, 2025
We’re excited to announce that Ash Alavijeh, our Head of Operations, will be attending the OBN Science Social in Stratford, London!
Today 🕕 Time: 18:00 - 20:00
📍 Location: Cancer Research Horizons, 2 Redman Place, London E20 1JQ
(https://lnkd.in/eQuhhzph)
Ash looks forward to meeting fellow attendees, engaging in insightful discussions, and exploring new opportunities for collaboration.
At Pharmidex, we are passionate about enhancing capabilities in drug discovery and development, and we’re always keen to connect with like-minded professionals.
If you're attending, don’t hesitate to say hello and have a chat! Looking forward to an evening of networking and innovation.
#Pharmidex #OBNScienceSocial #DrugDiscovery #Collaboration #Networking #PharmaInnovation
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
